BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 12, 2007
 |  BioCentury  |  Product Development

Doubling up for half-life

At least five replacement therapies are marketed for hemophilia, and it is relatively easy to make recombinant Factor VIII and Factor IX, the missing clotting factors that lead to the disease. As a result, companies generally compete by tailoring dosing methods and schedules to a broader set of patient preferences.

Under a pair of deals announced last week, Wyeth is turning to protein delivery partners to help develop second-generation products with longer half-lives. WYE (Madison, N.J.) markets ReFacto recombinant Factor VIII (rFVIII) for hemophilia A and also has the only marketed rFactor IX, BeneFIX, for hemophilia B. In 2006, WYE posted BeneFIX sales of $304 million and ReFacto sales of $65 million.

Prophylaxis of hemophilia involves the infusion of...

Read the full 591 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >